Abstract | BACKGROUND: METHODS: RESULTS: Patients who had a PS of 2-3 prior to undergoing HSCT experienced Grade 4 hematologic toxicities and Grade > or = 3 organ toxicities and died of either treatment-related complications or disease progression within 100 days from transplantation. By contrast, 10 of 11 patients who had a PS of 0-1 prior to undergoing HSCT experienced only short-lasting, Grade < or = 3 neutropenia and thrombocytopenia and no organ toxicity; 1 of 10 patients died of graft failure on Day +29 after undergoing HSCT. By Day +90, 100% donor chimerism was documented in all patients with a past history of heavy chemotherapy, whereas mixed donor chimerism was observed in the 4 patients with a past history of only 1 line of chemotherapy and/or immunotherapy prior to entering the HSCT program. Grade 2-3 acute GVHD occurred in 5 patients. Among patients with a follow-up > 100 days, 2 complete responses and 3 transitory partial responses were recorded. CONCLUSIONS: With this conditioning regimen, full donor chimerism was achieved rapidly only in patients who had received previous intensive chemotherapy. In a proportion of patients with refractory malignancies, allogeneic transplantation resulted in tumor regression. This novel therapeutic strategy may provide little benefit in patients with poor PS and rapidly progressing disease.
|
Authors | Paolo Pedrazzoli, Gian Antonio Da Prada, Giovanna Giorgiani, Roberta Schiavo, Alberto Zambelli, Eugenia Giraldi, Giuseppe Landonio, Franco Locatelli, Salvatore Siena, Gioacchino Robustelli Della Cuna |
Journal | Cancer
(Cancer)
Vol. 94
Issue 9
Pg. 2409-15
(May 01 2002)
ISSN: 0008-543X [Print] United States |
PMID | 12015766
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10491 |
Chemical References |
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Cyclophosphamide
- Vidarabine
- fludarabine
|
Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Agents, Alkylating
(administration & dosage)
- Breast Neoplasms
(surgery)
- Carcinoma, Renal Cell
(surgery)
- Child
- Cyclophosphamide
(administration & dosage)
- Female
- Hematopoietic Stem Cell Transplantation
- Hodgkin Disease
(surgery)
- Humans
- Kidney Neoplasms
(surgery)
- Male
- Melanoma
(surgery)
- Middle Aged
- Neoplasms
(therapy)
- Pilot Projects
- Sarcoma
(surgery)
- Survival Rate
- Transplantation Chimera
- Transplantation Conditioning
(methods)
- Transplantation, Homologous
- Treatment Outcome
- Vidarabine
(administration & dosage, analogs & derivatives)
|